Clinical Trials Logo
  1. Home
  2. Relapsed Ovarian Cancer
  3. NCT05479487

Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

Relapsed Ovarian Cancer Clinical Trial

Official title:
Fluzoparib Combined With Apatinib Versus Fluzoparib for Maintenance Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Randomized, Open Label, Controlled, Multicenter Trial

Clinical Trial Summary

This study is a Phase II randomized, open label, controlled, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib versus fluzoparib monotherapy for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma (including patients previous treated with a PARP inhibitor).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05479487
Study type Interventional
Source Fudan University
Contact Xiaohua Wu, Ph.D., MD
Phone +86 021-64175590
Email wu.xh@fudan.edu.cn
Status Not yet recruiting
Phase Phase 2
Start date August 1, 2022
Completion date September 1, 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01874353 - Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Phase 3
Not yet recruiting NCT06081595 - Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment Phase 2
Recruiting NCT04517357 - A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients Phase 2
Recruiting NCT04887961 - Reprab Study: PLD + Trabectedin Rechallenge Phase 2
Active, not recruiting NCT03534453 - Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Phase 3
Recruiting NCT05080556 - Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer Phase 2
Recruiting NCT05607329 - Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial N/A
Terminated NCT04999605 - A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer Phase 1/Phase 2
Completed NCT02825420 - Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
Recruiting NCT04713514 - OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC Phase 2